System inflammation and protein energy wasting correction in patients with chronic kidney disease

Keywords: chronic kidney disease, protein-energy wasting, systemic inflammation, interleukin 1β, interleukin 6, interleukin 8, C-reactive protein, levocarnitine, aminoacids


Protein-energy wasting as a manifestation of nutritional disorders is one of the central complications in chronic kidney disease (CKD) and largely determines quality and life expectancy. Both decrease in nutritional status and systemic inflammation are independent predictors of general and cardiovascular mortality. Mutual stimulation of these factors determines the search for new directions for the treatment of patients with CKD.

The aim of the research was to study the state of systemic inflammation and malnutrition in CKD by assessing the level of interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8) and C-reactive protein (CRP) and serum albumin and to study the effectiveness of therapy with levocarnitine and a solution of a mixture of ketanalogs of irreplaceable and substitute amino acids for parenteral administration in CKD.

Results. The level of markers of inflammation IL-1β, IL-6, IL-8 and CRP progressively increased in parallel with the development of renal failure. The level of albuminemia decreased from the I to the V stage of the CKD, in which among patients with glomerular filtration rate 15 - 45 ml/(min · 1.17 m2) in 14% there was a malnutrition of a mild degree; whereas, at CKD of the V stage, malnutrition of a mild degree was in 16% of patients, moderate malnutrition was detected in 10% of the subjects, and 5% suffered from severe malnutrition. After standard therapy the least effect was observed. A more significant decrease in the level of proinflammatory cytokines and CRP was observed with the additional acquisition of levocarnitine. An even better effect was observed in the group of patients receiving Nefrotect. The most significant level of inflammation markers decrease was seen in the group receiving combined Nephrotect therapy with levocarnitine Nefrotect, where the concentration of proinflammatory interleukins decreased more than threefold compared with baseline. The level of albuminemia reached the highest level with combined therapy, compared with standard therapy.

Conclusions. Nutritional status of patients with CKD decreases progressively in the fall of kidney function, reaching the level of mild malnutrition at CKD stage III and the severe degree of malnutrition at CKD stage V. With the progression of renal failure, activation of the systemic inflammation, in particular, the increase of the level of circulating in the blood of interleukin 1β, interleukin 6, interleukin 8 and CRP was seen. The efficacy of treatment of systemic inflammation and protein-energy insufficiency by levocarnitine and a solution of a mixture of ketonalogs ofirreplaceable and substitute aminoacids in the cohort of patients with CKD of the І-V stages is proved. This combined therapy significantly lowered the level of interleukin 1β, interleukin 6, interleukin 8, and CRP, as well as elevated serum albumin levels in patients with CKD.


Download data is not yet available.


Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391–8. doi:

Dudar I, Shymova A, Krasyuk E, Burzhynska I. Disturbances of nutrinional status in patients treated by peritoneal dialysis. Ukr. zhurn. nefrolohii ta dializu. 2016;2(50):56-61. [In Ukrainian]. doi:

Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K,et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 2013 Dec;84(6):1096-107.doi: 10.1038/ki.2013.147.

Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Management of protein-energy wasting in nondialysis-dependent chronic kidney disease: Reconciling low protein intake with nutritional therapy. Am J Clin Nutr. 2013;97(6):1163–1177. doi: 10.3945/ajcn.112.036418.

Amparo FC, Cordeiro AC, Carrero JJ, Cuppari L, Lindholm B, Amodeo C, et al. Malnutrition-inflammation score is associated with handgrip strength in nondialysis-dependent chronic kidney disease patients. J Ren Nutr. 2013;23(4):283–7. doi: 10.1053/j.jrn.2012.08.004.

Kim Y, Molnar MZ, Rattanasompattikul M, Hatamizadeh P, Benner D, Kopple JD, et al. Relative contributions of inflammation and inadequate protein intake to hypoalbuminemia in patients on maintenance hemodialysis. Int Urol Nephrol. 2013;45(1):215–227. doi: 10.1007/s11255-012-0170-8.

Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, etal. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013;28(7):1936–1945. doi: 10.1093/ndt/gfs368.

den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Penne EL, Mazairac AH, et al. Clinical predictors of decline in nutritional parameters over time in ESRD. Clin J Am Soc Nephrol. 2014;9(2):318–325. doi: 10.2215/CJN.04470413.

Riella MC. Nutritional evaluation of patients receiving dialysis for the management of proteinenergy wasting: What is old and what is new? J Ren Nutr. 2013;23(3):195–198. doi: 10.1053/j.jrn.2013.01.023.

Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, et al. Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int. 2002;(62):593–601.doi:

Deger SM, Sundell MB, Siew ED, Egbert P, Ellis CD, Sha F, et al. Insulin resistance and protein metabolism in chronic hemodialysis patients. J Ren Nutr. 2013;(23):59–66. doi: 10.1053/j.jrn.2012.08.013.

von Haehling S, Lainscak M, Springer J,Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;(121):227–252. doi:

Cuppari L, de Carvalho AB, Avesani CM, Kamimura MA, Dos Santos Lobão RR, Draibe SA. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol. 2004;(15):2933–9.doi:

Nagler EV, Webster AC, Vanholder R,  Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012;(27):3736–3745. doi: 10.1093/ndt/gfs295.

Jhamb M, Argyropoulos C, Steel JL, Plantinga L, Wu AW, Fink NE, et al. Correlates and outcomes of fatigue among incident dialysis patients. Clin J Am Soc Nephrol. 2009;(4):1779–1786. doi: 10.2215/CJN.00190109.

Carrero JJ. Identification of patients with eating disorders: clinical and biochemical signs of appetite loss in dialysis patients. J Ren Nutr 2009;(19): 10–5. doi: 10.1053/j.jrn.2008.10.004.

Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens. 2010;(19):37–42.doi: 10.1097/MNH.0b013e328332fc2b.

Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int. 2009;(76):567–575. doi: 10.1038/ki.2009.200.

Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004;(10):524–9.

Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant. 2010;(25):901–6. doi: 10.1093/ndt/gfp587.

de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;(20):2075–2084. doi: 10.1681/ASN.2008111205.

How to Cite
Chaikovska, M. I., & Martynyuk, L. P. (2019). System inflammation and protein energy wasting correction in patients with chronic kidney disease. Ukrainian Journal of Nephrology and Dialysis, (2(62), 41-47.